Gilead Sciences has announced a partnership with Precision Biosciences to develop a cure for hepatitis B virus infections. The two companies will work together on the development of an experimental drug that targets and destroys the virus. Early laboratory tests have shown Arcus's DNA-cutting enzymes can target and eradicate the virus’s DNA, as well as the viral cccDNA in human liver cells. Precision will oversee preclinical development. Gilead will arrange clinical testing and taking the drugs to market, if the treatment is approved by the US Food and Drug Administration.
Gilead Sciences has announced a partnership with Precision Biosciences to develop a cure for hepatitis B virus infections. Funding both research and development, Gilead is backing Arcus, Precision's gene-editing technology. Early laboratory tests have shown Arcus's DNA-cutting enzymes can target and eradicate the virus’s DNA, as well as the viral cccDNA in human liver cells. Precision will oversee preclinical development. Gilead will arrange clinical testing and taking the drugs to market, if the treatment is approved by the US Food and Drug Administration.